SAN

79.12

+1.4%↑

ORNBV.FI

68.25

+3.72%↑

SAN

79.12

+1.4%↑

ORNBV.FI

68.25

+3.72%↑

SAN

79.12

+1.4%↑

ORNBV.FI

68.25

+3.72%↑

SAN

79.12

+1.4%↑

ORNBV.FI

68.25

+3.72%↑

SAN

79.12

+1.4%↑

ORNBV.FI

68.25

+3.72%↑

Search

Sartorius AG

Atidarymo kaina

SektoriusSveikatos priežiūra

214.3 2.44

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

207.2

Max

215.6

Pagrindiniai rodikliai

By Trading Economics

Pajamos

26M

56M

Pardavimai

-29M

899M

P/E

Sektoriaus vid.

93.504

67.147

Pelnas, tenkantis vienai akcijai

1.21

Dividendų pajamingumas

0.34

Pelno marža

6.251

Darbuotojai

14,242

EBITDA

-9.6M

258M

Rekomendacijos

By TipRanks

Rekomendacijos

Pirkti

12 mėnesių prognozė

+26.92% upside

Dividendai

By Dow Jones

Dividendų pajamingumas

Sektoriaus vid.

0.34%

2.36%

Rinkos statistika

By TradingEconomics

Rinkos kapitalizacija

-1.6B

15B

Ankstesnė atidarymo kaina

211.86

Ankstesnė uždarymo kaina

214.3

Naujienos nuotaikos

By Acuity

16%

84%

33 / 348 reitingas Healthcare

Techninis įvertinimas

By Trading Central

Pasitikėjimas

Bearish Evidence

Sartorius AG Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2026-04-29 23:53; UTC

Uždarbis

Naver Posts Weaker First-Quarter Earnings

2026-04-29 23:41; UTC

Karštos akcijos

Stocks to Watch: Meta Platforms, Alphabet, Qualcomm, Amazon.com

2026-04-29 23:55; UTC

Uždarbis

Samsung Electronics 1Q Net Profit Beat FactSet-Compiled Consensus

2026-04-29 23:54; UTC

Uždarbis

Samsung Electronics 1Q Net KRW47.225T Vs. Net KRW8.223T >005930.SE

2026-04-29 23:52; UTC

Uždarbis

Samsung Electronics 1Q Oper Pft KRW57.233T Vs. Pft KRW6.685T >005930.SE

2026-04-29 23:51; UTC

Uždarbis

Samsung Electronics 1Q Rev KRW133.873T Vs. KRW79.141T >005930.SE

2026-04-29 23:51; UTC

Rinkos pokalbiai

Nikkei May Fall Amid Uncertainty Over Mideast Conflict -- Market Talk

2026-04-29 23:34; UTC

Rinkos pokalbiai

Gold Edges Higher on Likely Technical Recovery -- Market Talk

2026-04-29 23:24; UTC

Uždarbis

CSC Financial 1Q Results Supported By Higher Income From Fees, Commission>6066.HK

2026-04-29 23:24; UTC

Uždarbis

CSC Financial Gains From Changes in Fair Value on Financial Assets Also Aided Results>6066.HK

2026-04-29 23:24; UTC

Uždarbis

CSC Financial 1Q Net CNY3.67B Vs. Net CNY1.84B >6066.HK

2026-04-29 23:24; UTC

Uždarbis

CSC Financial 1Q Rev CNY7.70B Vs. CNY4.74B >6066.HK

2026-04-29 23:22; UTC

Uždarbis

China Longyuan 1Q Net CNY1.70B, Down 14%

2026-04-29 23:22; UTC

Uždarbis

China Longyuan: Power Generation Down 2.9% as of End-March

2026-04-29 23:20; UTC

Uždarbis

China Longyuan: 1Q Rev From Wind Power Fell, Rev From Solar Power Rose

2026-04-29 23:20; UTC

Uždarbis

China Longyuan 1Q Rev CNY7.87B, Down 3.6%

2026-04-29 23:19; UTC

Uždarbis

China Vanke 1Q Loss CNY5.95B Vs. Loss CNY6.25B >000002.SZ

2026-04-29 23:19; UTC

Uždarbis

China Vanke: Weak China Real Estate Market Continue to Weigh on Results>000002.SZ

2026-04-29 23:19; UTC

Uždarbis

China Vanke 1Q Rev CNY28.93B Vs. CNY37.99B >000002.SZ

2026-04-29 23:19; UTC

Uždarbis

China Vanke 1Q Loss Narrows>000002.SZ

2026-04-29 23:18; UTC

Uždarbis

Naver1Q Net Profit Missed FactSet-Compiled Consensus

2026-04-29 23:17; UTC

Uždarbis

Naver 1Q Net KRW291.00B Vs. Net KRW423.70B >035420.SE

2026-04-29 23:15; UTC

Uždarbis

Naver 1Q Oper Pft KRW541.80B Vs. Pft KRW505.30B >035420.SE

2026-04-29 23:15; UTC

Uždarbis

Naver 1Q Rev KRW3.241T Vs. KRW2.787T >035420.SE

2026-04-29 23:13; UTC

Uždarbis

CICC: Gains From Investments in Financial Instruments Also Aided Results >3908.HK

2026-04-29 23:12; UTC

Uždarbis

CICC Results Supported by Increase in Fee, Commission Income >3908.HK

2026-04-29 23:11; UTC

Uždarbis

CICC 1Q Rev CNY8.83B Vs. CNY5.72B >3908.HK

2026-04-29 23:11; UTC

Uždarbis

CICC 1Q Net CNY3.58B Vs. Net CNY2.04B >3908.HK

2026-04-29 23:04; UTC

Uždarbis

Microsoft Reports Strong Cloud Growth, but Questions About AI Returns Persist -- WSJ

2026-04-29 23:04; UTC

Uždarbis

Meta Reports Big Revenue Jump and Projected Spending Increase -- 3rd Update

Akcijų palyginimas

Kainos pokytis

Sartorius AG Prognozė

Kainos tikslas

By TipRanks

26.92% į viršų

12 mėnesių prognozė

Vidutinis 265 EUR  26.92%

Aukščiausias 307 EUR

Žemiausias 220 EUR

Remiantis 13 „Wall Street“ analitikais, siūlančiais 12 mėnesių tikslines Sartorius AG kainas – Dist per pastaruosius 3 mėnesius.

Bendras įvertinimas

By TipRanks

Pirkti

13 ratings

8

Pirkti

5

Laikyti

0

Parduoti

Techninis įvertinimas

By Trading Central

227 / 232Palaikymas ir pasipriešinimas

Trumpalaikis periodas

Bearish Evidence

Vidutinės trukmės periodas

Neutral Evidence

Ilgalaikis periodas

Weak Bullish Evidence

Rinkos nuotaikos

By Acuity

33 / 348 reitingas Sveikatos priežiūra

Naujienos nuotaikos

Labai stiprus bulių rinkos įrodymas

Svyravimai

Žemiau vidurkio

Naujienų apimtis (RCV)

Aukščiau vidurkio

Finansinės naujienos

Pardavimo ir administravimo išlaidos

Veiklos sąnaudos

Ikimokestinis pelnas

Pardavimai

Pardavimo savikaina

Bendrasis pelnas iš pardavimo

Skolų palūkanų išlaidos

EBITDA

Veiklos pelnas

$

Apie bendrovę Sartorius AG

Sartorius Aktiengesellschaft provides bioprocess solutions and lab products and services in the United States and internationally. The company offers multi-parallel, benchtop, single-use, stainless steel, cell culture, rocking motion, and microbial bioreactors, and software apps for bioreactors and cell culture shake flask; fermenters; cell culture media products; cellcelector flex, incubator flowbox, nanowell arrays, and capillaries and tips; fluid management products; microbiology products; and Ultrafiltration membrane filters, glass and quartz microfiber filters, clarification, syringeless and in-line filters, lab chromatography, and filters and blotting papers. It also provides live-cell analysis systems, reagents and consumables, support and services, and live-cell imaging and analysis software; contract manufacturing and integration, membranes and devices, weigh cells, and data analytics, as well as connectivity, and pipetting and dispensing modules; electronic and mechanical pipettes, pipette tips, bottle-top dispensers, and pipette controllers and accessories; process automation platform and software, sensors and analyzers, biomolecule analysis tools, and data analytics software; chromatography consumables, columns, and systems; and biolayer interferometry products. In addition, the company offers water purification systems; surface plasmon resonance; lab balances, pipette calibration, mass comparators and metrology, moisture analyzers, equipment manufacturer cells, weights and weight sets, paint mixing solutions, and weighing accessories; and process filtration. Further, the company provides bioprocess consulting and engineering, biologics testing, media and process, instrument, octet service and support, and validation services. It serves the life science research, biopharmaceutical manufacturing, pharmaceutical quality control, cell and gene therapy, and applied industries. Sartorius Aktiengesellschaft was founded in 1870 and is headquartered in Göttingen, Germany.
help-icon Live chat